{'fraction_non_alphanumeric': 0.030330062444246207, 'fraction_numerical': 0.0, 'mean_word_length': 5.925925925925926, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Novel therapies to prevent diabetic retinopathy.

Normal retina (left); retina of a patient with diabetes and proliferative retinopathy (right). "The eye with diabetic retinopathy provides a unique 'window' for noninvasively studying the vascular damage diabetes causes in the kidney and other organs," said Robert Goldstein, MD, PhD, vice president for research, Juvenile Diabetes Foundation International. THANKS TO recent advances in understanding how hyperglycemia may damage blood vessels in the eyes of patients with diabetes, several novel therapies for preventing diabetic retinopathy are now under study. The latest research on potential therapies was discussed at the Juvenile Diabetes Foundation International (JDFI) Oxford Conference on Diabetic Retinopathy, at St John's College, Oxford University, Oxford, England, in September. The conference, which was sponsored by the JDFI (headquartered in New York, NY) and the European Association for the Study of Diabetes, brought together many of the world's leading investigators of the pathogenic mechanisms behind diabetic retinopathy and other complications of